The methods of use of anti-Covid monoclonal antibodies are changing. This was announced by the Italian drug agency Aifa, informing that it had given “a positive opinion on the use of the sotrovimab antibody, which has shown a favorable benefit / risk ratio even against the main circulating variants of Sars-CoV-2”. Furthermore – according to the results of the international study Recovery, which showed “a benefit in terms of mortality and reduction in the risk of disease progression of treatment with casirivimab and imdevimab in adult patients hospitalized for Covid-19, even on conventional oxygen therapy (not at high flows and not in mechanical ventilation) and with negative serology for Sars-CoV-2 anti-Spike IgG antibodies “- the national regulatory body has decided to” extend the possible use of the casirivimab / imdevimab combination in this subpopulation ” .
“In consideration of the epidemiological scenario of prevalence of the variants of Sars-CoV-2, rapidly mutated in the last few weeks”, the Aifa warns that “the monoclonal antibodies against Sars-CoV-2 currently available, despite having overlapping indications for use, they differ from each other, on the basis of recent literature evidence, for their ability to neutralize the different circulating variants “. In particular, “all anti Sars-CoV-2 antibodies available in Italy (bamlanivamb / etesevimab, casirivimab / imdevimab and sotrovimab) maintain adequate antiviral activity against the Alpha (lineage B.1.1.7) and Delta (lineage B .1.617.2), while the neutralizing activity of the bamlanivamb / etesevimab combination, unlike the other available monoclonal antibodies (casirivimab / imdevimab and sotrovimab), is strongly inhibited against the Beta (B.1.351) and Gamma (P.1) variants ) “.
“Therefore, in the geographical areas where there is a circulation of the Beta and Gamma variants”, the agency suggests to “use the monoclonal antibodies casirivimab / imdevimab and sotrovimab, effective against all variants, or to precede the initiation of therapy by genotyping / sequencing “.
Also for the approval of sotrovimab, the AIFA points out, “the procedure of authorization for temporary distribution by decree of the Minister of Health was used, and this antibody is therefore added to the others already available (bamlanivamb / etesevimab and casirivimab / imdevimab) .
Read Also
- Manufacturers agree on the future European combat aircraft Nov 18, 2022
- Electricity: French consumption decreased by 5.4% over one week Nov 16, 2022
- Nancy: One year suspended prison sentence required against caregivers after the death of young Timéo at the CHRU Nov 23, 2022
- Paint receives its first update in years: it will have dark mode in Windows 11 Aug 20, 2021
- Summer live: from 23 August it airs at the usual time Aug 20, 2021
- “Everything Explained”: Plants and Sex, What a Story! Nov 25, 2022
- ‘Argentina Programa’: how to access the subsidy of 100,000 pesos to buy computers Aug 9, 2021
The determinations on the green light to sotrovimab and on the extension of use of casirivimab / imdevimab “will be published in the Official Gazette of August 6, 2021 – concludes the agency – and will be effective from the day following publication”.
!function(f,b,e,v,n,t,s)
{if(f.fbq)return;n=f.fbq=function(){n.callMethod?
n.callMethod.apply(n,arguments):n.queue.push(arguments)};
if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version=’2.0′;
n.queue=[];t=b.createElement(e);t.async=!0;
t.src=v;s=b.getElementsByTagName(e)[0];
s.parentNode.insertBefore(t,s)}(window, document,’script’,
‘https://connect.facebook.net/en_US/fbevents.js’);
fbq(‘init’, ‘415374439673532’);
fbq(‘track’, ‘PageView’);